Precigen 관리

관리 기준 확인 2/4

Precigen CEO는 Helen Sabzevari, Jan2020 에 임명되었습니다 의 임기는 4.83 년입니다. 총 연간 보상은 $ 3.72M, 26.9% 로 구성됩니다. 26.9% 급여 및 73.1% 보너스(회사 주식 및 옵션 포함). 는 € 1.93M 가치에 해당하는 회사 주식의 0.77% 직접 소유합니다. 1.93M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 10.6 년입니다.

주요 정보

Helen Sabzevari

최고 경영자

US$3.7m

총 보상

CEO 급여 비율	26.9%
CEO 임기	4.8yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	10.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Helen Sabzevari 의 보수는 Precigen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$135m
Mar 31 2024	n/a	n/a	-US$97m
Dec 31 2023	US$4m	US$1m	-US$96m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$79m
Dec 31 2022	US$3m	US$1m	-US$80m
Sep 30 2022	n/a	n/a	-US$84m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$108m
Dec 31 2021	US$3m	US$1m	-US$111m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	US$20m	US$1m	-US$104m
Sep 30 2020	n/a	n/a	-US$100m
Jun 30 2020	n/a	n/a	-US$122m
Mar 31 2020	n/a	n/a	-US$138m
Dec 31 2019	US$1m	US$500k	-US$169m
Sep 30 2019	n/a	n/a	-US$373m
Jun 30 2019	n/a	n/a	-US$381m
Mar 31 2019	n/a	n/a	-US$414m
Dec 31 2018	US$3m	US$500k	-US$375m

보상 대 시장: Helen 의 총 보상 ($USD 3.72M )은 German 시장( $USD 788.48K ).

보상과 수익: 회사가 수익성이 없는 동안 Helen 의 보상이 증가했습니다.

CEO

Helen Sabzevari (62 yo)

4.8yrs

테뉴어

US$3,719,061

보상

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...

리더십 팀

이름	위치	테뉴어	보상	소유권
Randal Kirk	Executive Chairman	16.8yrs	US$600.00k	0.40% € 996.9k
Helen Sabzevari	President	4.8yrs	US$3.72m	0.77% € 1.9m
Harry Thomasian	Chief Financial Officer	3.1yrs	US$1.13m	0.080% € 199.8k
Rutul Shah	Chief Operating Officer	no data	US$1.04m	0.073% € 182.7k
Donald Lehr	Chief Legal Officer & Corporate Secretary	13.8yrs	US$1.06m	0.19% € 468.7k
Jeffrey Perez	Senior Vice President of Intellectual Property Affairs	10.3yrs	US$872.09k	0.26% € 647.3k
Steven Harasym	VP & Head of Investor Relations	6.8yrs	데이터 없음	데이터 없음
Rob Russell	VP & Head of Human Resources	no data	데이터 없음	데이터 없음
Douglas Brough	Senior VP & Head of Research	no data	데이터 없음	데이터 없음
Bryan Butman	Senior VP & Head of CMC	no data	데이터 없음	데이터 없음
Amy Lankford	Senior VP & Head of Clinical Operations and Regulatory Affairs	1.4yrs	데이터 없음	데이터 없음
Phil Tennant	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: I5X 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Randal Kirk	Executive Chairman	16.8yrs	US$600.00k	0.40% € 996.9k
Helen Sabzevari	President	4.4yrs	US$3.72m	0.77% € 1.9m
Jeffrey Kindler	Independent Director	13yrs	US$319.00k	0.14% € 342.6k
Fred Hassan	Independent Director	8.4yrs	US$306.50k	0.36% € 897.0k
Cesar Alvarez	Independent Director	16.8yrs	US$312.50k	0.20% € 496.4k
James Turley	Lead Independent Director	10.6yrs	US$312.50k	0.16% € 411.5k
Steven Frank	Independent Director	16.8yrs	US$300.00k	0.36% € 892.1k
Nancy Agee	Independent Director	less than a year	데이터 없음	0.0061% € 15.3k
Vinita Gupta	Independent Director	7.6yrs	US$306.50k	0.16% € 396.9k

10.6yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: I5X 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.6 년).

Precigen 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Independent Director recently bought €630k worth of stock

Insufficient new directors

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Chief Financial Officer recently bought €51k worth of stock

Recent updates

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Precigen Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.082 loss in 2Q 2023)

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New major risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

New major risk - Share price stability

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Precigen, Inc., Annual General Meeting, Jul 05, 2024

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.099 loss in 1Q 2023)

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

Full year 2023 earnings released: US$0.39 loss per share (vs US$0.40 loss in FY 2022)

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Forecast to breakeven in 2026

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.038 loss in 3Q 2022)

Independent Director recently bought €630k worth of stock

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Second quarter 2023 earnings released: US$0.082 loss per share (vs US$0.13 loss in 2Q 2022)

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

First quarter 2023 earnings released: US$0.099 loss per share (vs US$0.12 loss in 1Q 2022)

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Now 20% undervalued after recent price drop

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Third quarter 2022 earnings released: US$0.038 loss per share (vs US$0.15 loss in 3Q 2021)

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Chief Financial Officer recently bought €51k worth of stock

Independent Director recently sold €111k worth of stock

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.10 loss in 2Q 2021)

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

First quarter 2022 earnings released: US$0.096 loss per share (vs US$0.11 loss in 1Q 2021)

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022

Precigen, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Precigen, Inc Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Insufficient new directors

Executive Chairman recently bought €3.2m worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

VP of Finance & Accounting and Principal Accounting Officer D. Osborne has left the company

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 1Q 2020)

Chief Financial Officer has left the company

Revenue misses expectations

Full year 2020 earnings released: US$0.62 loss per share (vs US$1.10 loss in FY 2019)

Precigen, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $112.5 million.

Precigen, Inc. Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

New 90-day high: €8.85

Precigen, Inc. Provides Latest Clinical Developments At Virtual R&D Update Event

Zhang Investor Law Alerts Investors to December 4 Deadline in Securities Class Action Lawsuit Against Precigen, Inc

New 90-day high: €6.20